Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Buy
59
MBX Quote, Financials, Valuation and Earnings
Last price:
$31.08
Seasonality move
:
-40.79%
Day range:
$30.53 - $31.56
52-week range:
$4.81 - $35.55
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.68x
Volume:
429.6K
Avg. volume:
818.4K
1-year change:
54.81%
Market cap:
$1B
Revenue:
--
EPS (TTM):
-$2.39
Analysts' Opinion
-
Consensus RatingMBX Biosciences, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 0 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $59.25, MBX Biosciences, Inc. has an estimated upside of 91.75% from its current price of $31.07.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $18.00 representing 100% downside risk from its current price of $31.07.
Fair Value
-
According to the consensus of 8 analysts, MBX Biosciences, Inc. has 91.75% upside to fair value with a price target of $59.25 per share.
MBX vs. S&P 500
-
Over the past 5 trading days, MBX Biosciences, Inc. has overperformed the S&P 500 by 6.29% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
MBX Biosciences, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
MBX Biosciences, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter MBX Biosciences, Inc. reported revenues of --.
Earnings Growth
-
MBX Biosciences, Inc. has grown year-over-year earnings for 0 quarters straight. In the most recent quarter MBX Biosciences, Inc. reported earnings per share of -$0.63.
Enterprise value:
647M
EV / Invested capital:
1.67x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.29x
EV / Free cash flow:
-8.20x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$335K
Return On Assets:
-28.18%
Net Income Margin (TTM):
--
Return On Equity:
-29.36%
Return On Invested Capital:
-29.32%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$176K | -$252K | -$335K | -$100K | -$100K | |
| Operating Income | -- | -$59.6M | -$90.9M | -$19.6M | -$23.9M | |
| EBITDA | -- | -$59.3M | -$90.5M | -$19.5M | -$23.8M | |
| Diluted EPS | -$0.71 | -$1.65 | -$2.39 | -$0.54 | -$0.63 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | $281.2M | $397.5M | |
| Total Assets | -- | -- | -- | $282.4M | $400.1M | |
| Current Liabilities | -- | -- | -- | $10.9M | $12.1M | |
| Total Liabilities | -- | -- | -- | $11M | $12.5M | |
| Total Equity | -- | -- | -- | $271.4M | $387.5M | |
| Total Debt | -- | -- | -- | $112K | $476K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -$49.8M | -$77.7M | -$14.7M | -$21.5M | |
| Cash From Investing | -- | -$122.2M | -$21.1M | -$100.8M | $17.1M | |
| Cash From Financing | -- | $234.3M | $189M | $235.8M | $187.8M | |
| Free Cash Flow | -- | -$50.6M | -$78.9M | -$14.7M | -$21.9M | |
MBX
Sector
Market Cap
$1B
$28.2M
Price % of 52-Week High
86.92%
50.25%
Dividend Yield
0%
0%
Shareholder Yield
-32.16%
-1.54%
1-Year Price Total Return
41.16%
-18.1%
Beta (5-Year)
--
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$30.98
200-day SMA
Buy
Level
$15.37
Bollinger Bands (100)
Buy
Level
12.52 - 27.64
Chaikin Money Flow
Sell
Level
-18.9M
20-day SMA
Buy
Level
$30.69
Relative Strength Index (RSI14)
Buy
Level
55.21
ADX Line
Buy
Level
25.34
Williams %R
Neutral
Level
-54.6416
50-day SMA
Buy
Level
$26.09
MACD (12, 26)
Buy
Level
1.28
25-day Aroon Oscillator
Buy
Level
80
On Balance Volume
Neutral
Level
43.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (32.9062)
Buy
CA Score
(Annual)
Level (-0.1137)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (7.8305)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.
Stock Forecast FAQ
In the current month, MBX has received 7 Buy ratings 0 Hold ratings, and 1 Sell ratings. The MBX average analyst price target in the past 3 months is $59.25.
-
Where Will MBX Biosciences, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that MBX Biosciences, Inc. share price will rise to $59.25 per share over the next 12 months.
-
What Do Analysts Say About MBX Biosciences, Inc.?
Analysts are divided on their view about MBX Biosciences, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that MBX Biosciences, Inc. is a Sell and believe this share price will drop from its current level to $18.00.
-
What Is MBX Biosciences, Inc.'s Price Target?
The price target for MBX Biosciences, Inc. over the next 1-year time period is forecast to be $59.25 according to 8 Wall Street analysts, 7 of them rate the stock a Buy, 1 rates the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MBX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for MBX Biosciences, Inc. is a Buy. 7 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MBX?
You can purchase shares of MBX Biosciences, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase MBX Biosciences, Inc. shares.
-
What Is The MBX Biosciences, Inc. Share Price Today?
MBX Biosciences, Inc. was last trading at $31.08 per share. This represents the most recent stock quote for MBX Biosciences, Inc.. Yesterday, MBX Biosciences, Inc. closed at $31.07 per share.
-
How To Buy MBX Biosciences, Inc. Stock Online?
In order to purchase MBX Biosciences, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get MBX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
MBX
Sector
P/E ratio
--
23.92x
PEG ratio
-0.29x
-0.01x
P/B ratio
2.68x
1.83x
Price / LTM sales
--
1.61x
Growth Metrics
MBX
Sector
Revenue growth
--
4.6%
Earnings growth
-16.28%
10.88%
Revenue (5-year growth)
--
6.46%
Earnings forecast
-$0.68
-$0.21
Profitability
MBX
Sector
Profitability FY 2024
-$244K
$3.5M
Return on invested capital
-29.32%
-31.84%
Return on assets
-28.18%
-27.96%
Return on equity
-29.36%
-37.63%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Mar
16
Estimated Next Earnings Date
Feb
5
Balance Sheet
MBX
Sector
Total cash
$391.7M
$26.3M
Short term investments
$212.8M
$25.7M
Total assets
$268.5M
$76.9M
Long term debt
$476K
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
89
GDXU alert for Dec 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 18.81% over the past day.
Sell
20
SMX alert for Dec 30
SMX (Security Matters) Plc [SMX] is down 27.67% over the past day.
Buy
72
GLTO alert for Dec 30
Galecto, Inc. [GLTO] is down 12.13% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
